- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04570956
Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia or Lobular Carcinoma In Situ
February 2, 2024 updated by: Amy C. Degnim
A Phase IIB Randomized Trial of Oral Tamoxifen vs. Topical 4-hydroxytamoxifen Gel vs. Control in Women With Atypical Hyperplasia or Lobular Carcinoma In Situ
The investigators plan to prospectively study breast tissue changes after a short course of Tamoxifen (Tam).
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Women with atypical hyperplasia (AH) and lobular carcinoma in situ (LCIS) are at increased risk of breast cancer (BC) (~1-2 % per year).
Over two decades ago, placebo-controlled randomized trials established that oral tamoxifen (20 mg/day) reduces breast cancer risk by 50% in generally defined high risk women, with ~70% reduction in women at high risk specifically due to atypical hyperplasia.[1]
Years later, the side effects and toxicity of oral tamoxifen at 20 mg/day remain a significant barrier to its uptake and longterm compliance.[2,
3] To address the issue of toxicity, two main strategies have been pursued: 1) using a lower dose of oral tamoxifen, and 2) using a topical formulation of tamoxifen to avoid systemic side effects.
The investigators will perform a prospective study of women with AH or LCIS who will take a short course of prevention therapy; breast tissue samples will be evaluated pre- and post-therapy to identify and evaluate very early biomarkers of response.
The overall goal of the study is to evaluate short-term changes in background breast tissue induced by either low-dose oral tamoxifen or topical 4-OHT gel in women with AH or LCIS.
Study Type
Interventional
Enrollment (Estimated)
104
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Denice Gehling, RN
- Phone Number: 507-538-1628
- Email: gehling.denice@mayo.edu
Study Contact Backup
- Name: Lisa R Seymour
- Email: seymour.lisa@mayo.edu
Study Locations
-
-
Illinois
-
Evanston, Illinois, United States, 60208
- Recruiting
- Northwestern University
-
Contact:
- Zachary Feldman
- Phone Number: 312-695-1476
- Email: zachary.feldman@northwestern.edu
-
Principal Investigator:
- Seema Khan, M.D.
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Recruiting
- Mayo Clinic
-
Contact:
- Lisa Seymour, B.S
- Phone Number: 5072727414
- Email: seymour.lisa@mayo.edu
-
Contact:
- Denice Gehling, R.N.
- Phone Number: 507-538-1628
- Email: gehling.denice@mayo.edu
-
Principal Investigator:
- Amy Degnim, M.D.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Willing to return to enrolling institution for follow-up
- Willing to complete required testing
- Ability to complete questionnaire by themselves or with assistance
- Female (sex that was assigned at birth)
- Ipsilateral intact breast with histology confirmation of atypical ductal or lobular hyperplasia, or LCIS, within the last 5 years, whether surgically excised or not.
- Eastern Cooperative Oncology Group (ECOG) performance status ≤1
- The effects of topical afimoxifene (4-OHT) gel on the developing human fetus at the recommended therapeutic dose are unknown. However, oral tamoxifen is Pregnancy Category D-positive evidence of human fetal risk. For this reason, and because triphenylethylene antiestrogens, including tamoxifen, are known to be teratogenic, women of childbearing potential and their male partners must agree to use at least one effective form of birth control (abstinence is not an allowed method) prior to study entry and for the duration of study participation, and for 2 months following the last dose of study medications (participant can resume oral birth control pills for effective birth control measures after post-treatment biopsy is done). Effective birth control methods during treatment are: copper and Mirena intrauterine device (IUD), diaphragm/cervical cap/shield, spermicide, contraceptive sponge, condoms. Tubal Ligation is an acceptable method of birth control. Women of childbearing potential must have a negative pregnancy test within five days before starting study medications. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately.
- Willingness to avoid exposing breast skin to natural or artificial sunlight (i.e. tanning beds) for the duration of the study.
- Participants must have acceptable organ and marrow function as judged by treating physician's evaluation of baseline laboratory data.
- Negative pregnancy (serum or urine) test if of childbearing potential and/or follicle stimulating hormone (FSH) to verify menopausal status.
Exclusion Criteria:
- Clinically suspicious mass/lesions
- Breast cancer in the past 5 years.
- Patients with any history of venous thromboembolic disease, regardless of timeframe (history of varicose veins and superficial phlebitis is allowed).
- Cytotoxic chemotherapy for any indication in last 2 years.
- Current pregnancy or lactation.
- History of other prior breast cancer-specific therapy within the previous 2 years (chemotherapy, anti-HER2 agents, endocrine agents, everolimus, CDK4-6 inhibitors).
- Cytotoxic chemotherapy for any indication in last 2 years.
- Prior use of selective estrogen receptor modulator (SERMS) or AIs including tamoxifen, raloxifene, anastrozole, letrozole, or exemestane for prevention or therapy within 5 years.
- Exogenous sex steroid, including oral contraceptive pill use within 1 month prior to pretreatment breast biopsy. Use of vaginally administered estrogens and hormone coated IUD such as Mirena is permitted.
- History of any prior ipsilateral breast radiotherapy. Previous unilateral radiation of the contralateral side is allowed.
- Skin lesions on the breast that disrupt the stratum corneum (e.g., eczema, ulceration).
- History of endometrial neoplasia
- Current smoker. Cessation for at least 6 weeks
- Current users of potent inhibitors of tamoxifen metabolism. The potent inhibitors of tamoxifen metabolism are: bupropion, cinacalcet, fluoxetine, paroxetine, quinidine.
- Participants may not be receiving any other investigational agents within 90 days of enrollment or during this study.
- History of allergic reactions to tamoxifen.
- Uncontrolled intercurrent illness that in the judgement of the treating physician would make them unsuitable for study participation
- Current use of anticoagulation medications.
- Patients who are breastfeeding.
- Hemoglobin < 10 g/dL (within 30 days of randomization).
- Leukocytes < 3,000/microliter (within 30 days of randomization).
- Platelets < 100,000/microliter (within 30 days of randomization).
- Total bilirubin > 1.5 x institutional upper limit of normal (ULN) (within 30 days of randomization).
- Aspartate aminotransferase (AST) serum glutamic oxaloacetic transaminase (SGOT) > 1.5 x ULN (within 30 days of randomization).
- Alanine aminotransferase (ALT) serum glutamate pyruvate transaminase (SGPT) > 1.5 x ULN (within 30 days of randomization).
- Alkaline phosphatase, S > 1.5 x ULN (within 30 days of randomization).
- Albumin, S > 1.5 x ULN (within 30 days of randomization).
- Protein, total, S > 1.5 x ULN (within 30 days of randomization).
- Creatinine > 1.5 x ULN (within 30 days of randomization).
- Patients who are taking any medications, herbal products, or over the counter (OTC) products that are moderate or strong CYP2D6 inhibitors or CYP3A inducers. Patients should also refrain from starting any drug or product with these properties during the study. This is to avoid any potential interactions with tamoxifen or 4-OHT.
- Identification of a clinically suspicious mass on examination.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Oral Tamoxifen 10 mg/day
|
Oral Tamoxifen 10 mg/day
Other Names:
|
Experimental: Control
Oral and gel placebo
|
placebo pill or placebo gel
Other Names:
|
Experimental: Topical 4-OHT (4-hydroxytamoxifen) gel 4 mg/each breast/day
Topical 4-OHT (4-hydroxytamoxifen) gel 4 mg/each breast/day +oral placebo |
Topical 4-OHT (4-hydroxytamoxifen) gel 4 mg/each breast/day
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The purpose of this research is to evaluate short-term changes in background breast tissue induced by oral tamoxifen or 4-OHT gel in women with atypical hyperplasia or lobular carcinoma in situ (LCIS).
Time Frame: 48 months
|
Treatment Evaluation/Measurement of Effect
|
48 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Amy Degnim, M.D., Mayo Clinic
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 26, 2021
Primary Completion (Estimated)
December 31, 2026
Study Completion (Estimated)
December 31, 2026
Study Registration Dates
First Submitted
September 28, 2020
First Submitted That Met QC Criteria
September 29, 2020
First Posted (Actual)
September 30, 2020
Study Record Updates
Last Update Posted (Estimated)
February 5, 2024
Last Update Submitted That Met QC Criteria
February 2, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Skin Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Breast Diseases
- Breast Neoplasms
- Neoplasms, Ductal, Lobular, and Medullary
- Carcinoma in Situ
- Carcinoma
- Hyperplasia
- Breast Carcinoma In Situ
- Carcinoma, Lobular
- Physiological Effects of Drugs
- Antineoplastic Agents
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Hormone Antagonists
- Bone Density Conservation Agents
- Estrogen Antagonists
- Selective Estrogen Receptor Modulators
- Estrogen Receptor Modulators
- Tamoxifen
- Afimoxifene
Other Study ID Numbers
- CA237607 (NCI)
- 19-011444 (Other Identifier: Mayo Clinic Institutional Review Board)
- NCI-2022-02973 (Other Identifier: CTRP (Clinical Trials Reporting Program))
- 5R01CA237607-05 (U.S. NIH Grant/Contract: NCI)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Atypical Lobular Hyperplasia
-
Mayo ClinicRecruitingBreast Carcinoma | Breast Atypical Ductal Hyperplasia | Breast Atypical Lobular Hyperplasia | Breast Lobular Carcinoma In SituUnited States
-
Ohio State University Comprehensive Cancer CenterNot yet recruitingBreast Carcinoma | Breast Atypical Ductal Hyperplasia | Breast Atypical Lobular Hyperplasia | Breast Lobular Carcinoma In Situ | Breast Sclerosing AdenosisUnited States
-
National Cancer Institute (NCI)CompletedBreast Atypical Ductal Hyperplasia | Breast Atypical Lobular Hyperplasia | Breast Ductal Carcinoma In Situ | Breast Lobular Carcinoma In Situ | Invasive Breast CarcinomaUnited States
-
NYU Langone HealthUnited States Department of DefenseCompletedAtypical Ductal Breast Hyperplasia | Lobular Carcinoma in Situ (LCIS) | Atypical Lobular Hyperplasia (ALH) of BreastUnited States
-
Mayo ClinicSusan G. Komen Breast Cancer FoundationCompletedLobular Carcinoma in Situ | Atypical Ductal Hyperplasia | Atypical Lobular HyperplasiaUnited States
-
Julie NangiaIncyte Corporation; Translational Breast Cancer Research ConsortiumRecruitingDuctal Carcinoma In Situ | Atypical Ductal Hyperplasia | Atypical Lobular Hyperplasia | Lobular Carcinoma In SituUnited States
-
University of WashingtonNational Cancer Institute (NCI); National Institute of Nursing Research (NINR)CompletedDuctal Breast Carcinoma in Situ | BRCA1 Mutation Carrier | BRCA2 Mutation Carrier | Atypical Ductal Breast Hyperplasia | Lobular Breast Carcinoma in Situ | Atypical Lobular Breast HyperplasiaUnited States
-
King's College LondonEnrolling by invitationDCIS | Atypical Ductal Hyperplasia | Atypical Lobular Hyperplasia | LCISUnited Kingdom
-
SWOG Cancer Research NetworkNational Cancer Institute (NCI)RecruitingAtypical Hyperplasia of the Breast | Lobular Breast Carcinoma In Situ | Pleomorphic Lobular Breast Carcinoma In SituUnited States, Guam
-
Lawson Health Research InstituteNot yet recruitingBreast Fibroadenoma | Lobular Carcinoma in Situ | Atypical Ductal Hyperplasia | Phyllodes Breast Tumor | Atypical Lobular Hyperplasia | Flat Epithelial Atypia | Phyllodes; Fibroadenoma | Radial Scar | Breast Papilloma | Complex Sclerosing Papillary Lesion of the Breast
Clinical Trials on Tamoxifen
-
Institut Cancerologie de l'OuestActive, not recruiting
-
Northwestern UniversityNational Cancer Institute (NCI)CompletedEstrogen Receptor-positive Breast Cancer | Ductal Breast Carcinoma in SituUnited States
-
Seoul National University HospitalRecruitingHormone Receptor-positive Breast Cancer | Premenopausal Breast CancerKorea, Republic of
-
European Institute of OncologyIstituto Oncologico Veneto IRCCS; Ente Ospedaliero Ospedali Galliera; Istituto...Not yet recruitingDuctal Carcinoma in Situ | RAD51C Gene Mutation | RAD51D Gene Mutation | PALB2 Gene Mutation | Lobular Carcinoma in Situ | ATM Gene Mutation | CDH1 Gene Mutation | CHEK2 Gene Mutation | BRCA MutationItaly
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)CompletedBreast Cancer | Stage IV Breast CancerUnited States, Canada, Peru
-
National Cancer Center, KoreaUnknown
-
Northwestern UniversityNational Cancer Institute (NCI); BHR Pharma, LLCRecruitingEstrogen Receptor Positive | Ductal Breast Carcinoma In SituUnited States
-
The Methodist Hospital Research InstituteMillennium Pharmaceuticals, Inc.CompletedEstrogen Receptor Positive Breast CancerUnited States
-
Kafrelsheikh UniversityNot yet recruiting
-
National Cancer Institute (NCI)Active, not recruitingRecurrent Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7United States